To determine whether PTEN restoration and CXCR2 depletion could reactivate antitumor immunity by remodulating the immune microenvironment of BmCRPCs, we analyzed MDSC (CD11b+Gr-1+) infiltration in tumor tissues after 2 weeks of treatment. The gene discussed is CXCR2; the disease is neoplasm.